financetom
Business
financetom
/
Business
/
F5 Shares Climb On Better-Than-Expected Q3 Results, Strong Forward Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
F5 Shares Climb On Better-Than-Expected Q3 Results, Strong Forward Guidance
Jul 29, 2024 2:03 PM

F5, Inc. ( FFIV ) shares are climbing after the company reported its third-quarter financial results Monday. Here's a look at the details from the report. 

The Details: F5 reported quarterly earnings of $3.36 per share, which beat the analyst consensus estimate of $2.97 by 13.13%. Quarterly sales came in at $695.495 million, which beat the analyst consensus estimate of $686.062 million by 1.37%.

Software revenue of $179 million grew 3% from the year-ago period. Systems revenue of $130 million represented a decline of 16% from the prior year. Global services revenue of $387 million grew 3% from the year-ago period. Gross margin was 83.1%.

Read Also: What’s Going On With Lululemon Stock?

“We delivered third-quarter revenue at the top end of our guidance range fueled by software growth and continued growth of our global services offerings,” said François Locoh-Donou, F5’s president and CEO. “In addition, our continued operating discipline enabled us to deliver earnings per share well above the high end of our guidance.”

Outlook: F5 said that based on visibility to fourth-quarter software demand, it now expects fiscal year revenue toward the top end of prior expectations at approximately $2.8 billion, or roughly flat with last year. F5 also raised its fiscal year earning growth expectations and now expects to deliver approximately 12% earnings growth, up from the prior growth outlook of 7% to 9%.

FFIV Price Action: According to Benzinga Pro, F5 shares are up 13.63% after-hours at $201.80 at the time of publication Monday.

Read Next: 

Carbon Revolution Stock Races On Chevrolet Corvette ZR1 Wheels

Image: Moondance from Pixabay

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Alerus Financial Keeps Quarterly Dividend at $0.21 per Share, Payable Oct. 10 to Holders of Record on Sept. 26
--Alerus Financial Keeps Quarterly Dividend at $0.21 per Share, Payable Oct. 10 to Holders of Record on Sept. 26
Sep 2, 2025
10:54 AM EDT, 09/02/2025 (MT Newswires) -- Price: 22.19, Change: -0.09, Percent Change: -0.38 ...
Eni's Current Valuation Makes Risk-Reward 'Less Compelling,' RBC Capital Says
Eni's Current Valuation Makes Risk-Reward 'Less Compelling,' RBC Capital Says
Sep 2, 2025
10:55 AM EDT, 09/02/2025 (MT Newswires) -- Eni (E) shares are due a breather after a strong run as its valuation is now comparable to peers and makes the risk-reward less compelling amid uncertainty over Chief Executive Claudio Descalzi's potential transition when his term ends in 2026, RBC Capital Markets said in a Tuesday report. The energy company's execution on...
What's Going On With Lucid Group Stock?
What's Going On With Lucid Group Stock?
Sep 2, 2025
Shares of Lucid Group Inc ( LCID ) are falling Tuesday as the electric vehicle maker begins trading on a split-adjusted basis. The company's 1-for-10 reverse stock split, which was approved by stockholders on August 18, became effective after the market closed on Friday. What To Know: The action consolidates every ten pre-split shares into one new share, a move...
Why Is United Therapeutics Stock Rallying On Tuesday?
Why Is United Therapeutics Stock Rallying On Tuesday?
Sep 2, 2025
United Therapeutics Corporation ( UTHR ) released data on Tuesday from its TETON-2 study evaluating the use of nebulized Tyvaso (treprostinil) Inhalation Solution for idiopathic pulmonary fibrosis (IPF). The study met its primary efficacy endpoint of demonstrating improvement in absolute forced vital capacity (FVC) relative to placebo. FVC is a standard pulmonary function test. Tyvaso demonstrated superiority over placebo for...
Copyright 2023-2026 - www.financetom.com All Rights Reserved